Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (Note: Input metadata referenced "Sanara Medtech Inc.", but the filing text identifies the registrant as Wound Management Technologies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: The company distributes FDA-cleared, collagen-based wound care products (CellerateRx) to healthcare providers, long-term care facilities, and government markets. Operations are currently limited, with manufacturing and warehousing outsourced.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $127,812 | $138,400 |
| Cost of Sales | $413,753 | $219,525 |
| Gross Profit (Loss) | $(285,941) | $(81,125) |
| Net Loss | $(810,536) | $(586,738) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.03) |
| Cash and Equivalents (End of Period) | $2,317 | $92,544 |
| Total Current Liabilities | $1,248,973 | $472,971 |
| Accumulated Deficit | $(15,583,114) | $(14,772,577) |
Liquidity: The company holds minimal cash ($2,317) against significant current liabilities ($1.25 million). Net cash used in operating activities for the six months was $603,895.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 7.65% year-over-year for the six-month period.
- Gross Margin Deterioration: The company reported a gross loss of $285,941 for the six months ended June 30, 2009, compared to a gross loss of $81,125 in the prior year period. Cost of sales increased significantly to $413,753.
- Increased Debt: Current liabilities more than doubled from $472,971 to $1,248,973. This includes a new related-party note payable of $620,070 and accrued interest of $10,809.
- Cash Burn: Cash on hand decreased from $1,142 at the start of the period to $2,317 at the end, despite financing inflows, due to significant operating cash outflows.
Guidance, Risks, and Contingencies
Going Concern: The filing explicitly states that conditions raise "substantial doubt" about the company's ability to continue as a going concern. The company has continuously incurred losses and requires additional financing to meet obligations for the next 12 months.
Delinquent Taxes: The company is delinquent on federal payroll taxes. As of June 30, 2009, unpaid taxes totaled approximately $203,000, with estimated penalties and interest of $168,000 included in current liabilities.
Related Party Dependence: The company relies heavily on advances from related parties (including the CEO/President) to fund operations. Some notes are currently in default.
Subsequent Event (Acquisition): On June 15, 2009, the company announced an agreement in principle to acquire BioPharma Management, Inc. for 5,000,000 shares of common stock. The transaction is subject to legal, financial, and technical reviews.
Legal Proceedings: The company is a defendant in a civil suit regarding stock transactions from 1997 and intends to defend vigorously.
Investor Verification Checklist
- Capital Sufficiency: Verify if the company has secured the additional debt or equity financing required to survive the next 12 months, given the "substantial doubt" disclosure.
- Tax Liability Resolution: Confirm the status of negotiations with the IRS regarding the $203,000 unpaid payroll taxes and $168,000 in penalties.
- Acquisition Status: Determine if the proposed acquisition of BioPharma Management, Inc. has closed or been abandoned, as this impacts share count and future operations.
- Related Party Defaults: Assess the risk of default on the $620,070 related-party note and the potential for conversion to equity or legal action by lenders.
- Revenue Sustainability: Evaluate the viability of the business model given that Cost of Sales ($413k) significantly exceeded Revenue ($127k) for the six-month period.